Belite Bio (BLTE) Change in Account Payables (2024 - 2025)

Belite Bio's (BLTE) quarterly Change in Account Payables came in at -$3000.0 in Q4 2025, up 62.5% year-on-year from -$1846.2 in Q4 2024, and up 62.5% quarter-over-quarter from -$8000.0 in Q4 2024.

Belite Bio (BLTE) Change in Account Payables (2024 - 2025) Analysis & Trends

Belite Bio's Change in Account Payables history runs 2 years deep, the most recent figure standing at -$3000.0 for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -42.19 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 35.60 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 16.86 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -3,000.00
Dec 31, 2025 -3,000.00
Dec 31, 2024 -8,000.00
Dec 31, 2024 -8,000.00